WASHINGTON – Voicing a sense of urgency, FDA Commissioner Margaret Hamburg unveiled a blueprint Wednesday aimed at making the agency a part of the solution, rather than the problem, in promoting innovation in the biotech industry.

WASHINGTON – Although the deadline has come and gone, biopharma is still in the dark about the regulations intended to shed light on how potential conflicts of interest are to be publicly reported.

WASHINGTON – The National Center for Advancing Translational Sciences (NCATS) didn't make the cut in a draft House subcommittee fiscal 2012 appropriations bill for the National Institutes of Health (NIH).

For industry observers who think biosimilars won't stand much of a chance against long-time market dominators in the U.S., Hospira Inc. has one word: Europe.

WASHINGTON – Hoping to avoid future "flash crashes" like the one that played havoc with the markets May 6, 2010, the SEC is proposing changes to the circuit breaker rules it adopted nearly 25 years ago.

WASHINGTON – With unexpected drug shortages becoming the norm, the FDA needs to reallocate its resources to better handle the crisis and improve how, when and what it communicates about those shortages, a group of stakeholders told the agency.

WASHINGTON – "Just make the drugs," doctors and patients frustrated with the nation's escalating drug shortages told biopharma Monday at an FDA workshop.

WASHINGTON – Knowing it's not a full cure, lawmakers are suggesting an early warning system as a first step in treating the drug shortage epidemic facing the nation.

Regulatory certainty. It’s something industry needs and investors want to see. It’s also one of the drivers for job creation. But it’s something our government doesn’t seem to get. Take the president’s repeated call for shorter data exclusivity for biologics, beginning in 2012. Just last year, Congress made 12 years the law of the land. Changing it now is a) premature, b) unnecessary and c) absolutely pointless. As we’ve reported in BioWorld Today, the FDA is not ready to be deluged with biosimilar applications. And the biosimilar user fees that will pay for the path won’t even be in place...